Combined with a recent study suggesting that EPHA7 mutations could serve as a potential predictive biomarker for immune checkpoint inhibitors in multiple cancers (32), our results suggest that EPHA7 mutation indicate a poor prognosis, and the use of immune checkpoint inhibitors in EPHA7-mutated pancreatic cancer patients may result in better clinical outcomes. Here, EPHA7 is linked to familial pancreatic carcinoma.